Clinical Trial Update: A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases [Phase 1]

View source ↗

Summary

This update describes the first-in-human Phase 1 trial of AO-252, an oral TACC3 protein-protein interaction inhibitor, in patients with advanced solid tumors wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Solid Tumors

Drugs mentioned

• AO-252

Snippet

Sponsor: A2A Pharmaceuticals Inc. | Conditions: Solid Tumor Malignancies, Brain Metastases From Solid Tumors | Phase 1 | Status: RECRUITING